Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:1784-1794
Published online before print October 1, 2007, doi: 10.1161/CIRCULATIONAHA.107.690180
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correction
Right arrow Correction (v116,pe514)
Right arrow All Versions of this Article:
116/16/1784    most recent
CIRCULATIONAHA.107.690180v2
CIRCULATIONAHA.107.690180v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Köhler, D.
Right arrow Articles by Eltzschig, H. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Köhler, D.
Right arrow Articles by Eltzschig, H. K.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ADENOSINE 5'-PHOSPHATE
Medline Plus Health Information
*Cardiomyopathy
*Heart Attack
Related Collections
Right arrow Other myocardial biology
Right arrow Cardiovascular Pharmacology
Right arrow Animal models of human disease
Right arrow Genetically altered mice
Right arrow Ischemic biology - basic studies
Right arrow Physiological and pathological control of gene expression
Right arrow Acute myocardial infarction

(Circulation. 2007;116:1784-1794.)
© 2007 American Heart Association, Inc.


Molecular Cardiology

CD39/Ectonucleoside Triphosphate Diphosphohydrolase 1 Provides Myocardial Protection During Cardiac Ischemia/Reperfusion Injury

David Köhler, PhD*; Tobias Eckle, MD*; Marion Faigle, BS; Almut Grenz, MD; Michel Mittelbronn, MD; Stefanie Laucher, BS; Melanie L. Hart, PhD; Simon C. Robson, MD; Christa E. Müller, PhD; Holger K. Eltzschig, MD, PhD

From the Department of Anesthesiology and Intensive Care Medicine (D.K., T.E., M.F., S.L., H.K.E.), Department of Pharmacology and Toxicology (A.G.), and Institute of Brain Research (M.M.), University Hospital, Tübingen, Germany; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital (M.L.H.), and Liver and Transplant Centers (S.C.R.), Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass; Pharmaceutical Institute, Pharmaceutical Sciences Bonn, University of Bonn, Bonn, Germany (C.E.M.); and Mucosal Inflammation Program, Department of Anesthesiology, University of Colorado Health Science Center, Denver (H.K.E.).

Correspondence to Holger K. Eltzschig, MD, PhD, Mucosal Inflammation Program, Department of Anesthesiology and Perioperative Medicine, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Campus Box B113, Denver, CO 80262. E-mail holger.eltzschig{at}uchsc.edu

Received January 12, 2007; accepted August 17, 2007.

Background— Extracellular adenosine, generated from extracellular nucleotides via ectonucleotidases, binds to specific receptors and provides cardioprotection from ischemia and reperfusion. In the present study, we studied ecto-enzymatic ATP/ADP-phosphohydrolysis by select members of the ectonucleoside triphosphate diphosphohydrolase (E-NTPDase) family during myocardial ischemia.

Methods and Results— As a first step, we used a murine model of myocardial ischemia and in situ preconditioning and performed pharmacological studies with polyoxometalate 1, a potent E-NTPDase inhibitor (Na6[H2W12O40]). Polyoxometalate 1 treatment increased infarct sizes and abolished beneficial effects of preconditioning. To define relative contributions of distinct E-NTPDases, we investigated transcriptional responses of E-NTPDases 1 to 3 and 8 to preconditioning. We noted robust and selective induction of E-NTPDase 1 (CD39) transcript and protein. Histological analysis of preconditioned myocardium localized CD39 induction to endothelia and myocytes. Cd39–/– mice exhibited larger infarct sizes with ischemia (cd39+/+ 43.0±3.3% versus cd39–/– 52%±1.8; P<0.05), and cardioprotection was abrogated by preconditioning (cd39+/+ 13.3%±1.5 versus cd39–/– 50.5%±2.8; P<0.01). Heightened levels of injury after myocardial ischemia and negligible preconditioning benefits in cd39–/– mice were corrected by infusion of the metabolic product (AMP) or apyrase. Moreover, apyrase treatment of wild-type mice resulted in 43±4.2% infarct size reduction (P<0.01).

Conclusions— Taken together, these studies reveal E-NTPDase 1 in cardioprotection and suggest apyrase in the treatment of myocardial ischemia.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
NeuroscientistHome page
G. Vangeison and D. A. Rempe
The Janus-Faced Effects of Hypoxia on Astrocyte Function
Neuroscientist, December 1, 2009; 15(6): 579 - 588.
[Abstract] [PDF]


Home page
PhysiologyHome page
T. Eckle, M. Koeppen, and H. K. Eltzschig
Role of Extracellular Adenosine in Acute Lung Injury
Physiology, October 1, 2009; 24(5): 298 - 306.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
S. Sugimoto, X. Lin, J. Lai, M. Okazaki, N. A. Das, W. Li, A. S. Krupnick, R. Chen, S. S. Jeong, G.A. Patterson, et al.
Apyrase treatment prevents ischemia-reperfusion injury in rat lung isografts
J. Thorac. Cardiovasc. Surg., September 1, 2009; 138(3): 752 - 759.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
J. Reutershan, I. Vollmer, S. Stark, R. Wagner, K.-C. Ngamsri, and H. K. Eltzschig
Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs
FASEB J, February 1, 2009; 23(2): 473 - 482.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. K. Eltzschig, D. Kohler, T. Eckle, T. Kong, S. C. Robson, and S. P. Colgan
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection
Blood, January 1, 2009; 113(1): 224 - 232.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. Eckle, L. Fullbier, A. Grenz, and H. K. Eltzschig
Usefulness of pressure-controlled ventilation at high inspiratory pressures to induce acute lung injury in mice
Am J Physiol Lung Cell Mol Physiol, October 1, 2008; 295(4): L718 - L724.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Eckle, D. Kohler, R. Lehmann, K. C. El Kasmi, and H. K. Eltzschig
Hypoxia-Inducible Factor-1 Is Central to Cardioprotection: A New Paradigm for Ischemic Preconditioning
Circulation, July 8, 2008; 118(2): 166 - 175.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. C. Morote-Garcia, P. Rosenberger, J. Kuhlicke, and H. K. Eltzschig
HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak
Blood, June 15, 2008; 111(12): 5571 - 5580.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Eckle, M. Faigle, A. Grenz, S. Laucher, L. F. Thompson, and H. K. Eltzschig
A2B adenosine receptor dampens hypoxia-induced vascular leak
Blood, February 15, 2008; 111(4): 2024 - 2035.
[Abstract] [Full Text] [PDF]